Lamas Cristina, Navarro Elena, Casterás Anna, Portillo Paloma, Alcázar Victoria, Calatayud María, Álvarez-Escolá Cristina, Sastre Julia, Boix Evangelina, Forga Lluis, Vicente Almudena, Oriola Josep, Mesa Jordi, Valdés Nuria
Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Endocr Connect. 2019 Oct;8(10):1416-1424. doi: 10.1530/EC-19-0321.
Primary hyperparathyroidism is the most frequent manifestation of multiple endocrine neoplasia type 1 (MEN1) syndrome. Bone and renal complications are common. Surgery is the treatment of choice, but the best timing for surgery is controversial and predictors of persistence and recurrence are not well known. Our study describes the clinical characteristics and the surgical outcomes, after surgery and in the long term, of the patients with MEN1 and primary hyperparathyroidism included in the Spanish Registry of Multiple Endocrine Neoplasia, Pheochromocytomas and Paragangliomas (REGMEN). Eighty-nine patients (49 men and 40 women, 34.2 ± 13 years old) were included. Sixty-four out of the 89 underwent surgery: a total parathyroidectomy was done in 13 patients, a subtotal parathyroidectomy in 34 and a less than subtotal parathyroidectomy in 15. Remission rates were higher after a total or a subtotal parathyroidectomy than after a less than subtotal (3/4 and 20/22 vs 7/12, P < 0.05), without significant differences in permanent hypoparathyroidism (1/5, 9/23 and 0/11, N.S.). After a median follow-up of 111 months, 20 of the 41 operated patients with long-term follow-up had persistent or recurrent hyperparathyroidism. We did not find differences in disease-free survival rates between different techniques, patients with or without permanent hypoparathyroidism and patients with different mutated exons, but a second surgery was more frequent after a less than subtotal parathyroidectomy.
原发性甲状旁腺功能亢进是1型多发性内分泌腺瘤综合征(MEN1)最常见的表现形式。骨骼和肾脏并发症很常见。手术是首选治疗方法,但手术的最佳时机存在争议,且持续性和复发性的预测因素尚不明确。我们的研究描述了西班牙多发性内分泌腺瘤、嗜铬细胞瘤和副神经节瘤登记处(REGMEN)中MEN1和原发性甲状旁腺功能亢进患者的临床特征以及术后和长期的手术结果。纳入了89例患者(49例男性和40例女性,年龄34.2±13岁)。89例患者中有64例接受了手术:13例行甲状旁腺全切除术,34例行甲状旁腺次全切除术,15例行小于次全切除术。甲状旁腺全切除或次全切除术后的缓解率高于小于次全切除术(3/4和20/22比7/12,P<0.05),永久性甲状旁腺功能减退无显著差异(1/5、9/23和0/11,无统计学意义)。中位随访111个月后,41例接受长期随访的手术患者中有20例出现持续性或复发性甲状旁腺功能亢进。我们未发现不同手术技术、有无永久性甲状旁腺功能减退的患者以及不同突变外显子的患者之间无病生存率存在差异,但小于次全切除术后再次手术更为常见。